CEDRA Corporation, a division of Worldwide Clinical Trials, announced that it has purchased the Gyrolab™ xP workstation for use in its bioanalytical research, specifically for ligand binding analysis. CEDRA is employing the new Gyrolab in its Ligand Binding Assay (LBA) laboratory in Austin, Texas.
The Gyrolab's technology changes the multistep process involved in conventional LBA applications into single procedures. The Gyrolab also has the ability to integrate assay steps for protein quantification immunoassays.
“We believe the addition of the Gyrolab to our LBA laboratories is significant and represents our dedication to enhancing the capabilities offered to the biopharmaceutical research industry,” said William Nowatzke, Ph.D., Director, Ligand Binding Assay Group, CEDRA Corporation. “A key driver to our business is the dedication to staying on the forefront of technology.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.